Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy

Blood (2023) 142 (Supplement 1): 3504.

https://doi.org/10.1182/blood-2023-190388

Published: 2023

Journal Articles

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 3479.

https://doi.org/10.1182/blood-2023-182430

Published: 2023

Journal Articles

Standardization of Outpatient Care after CAR-T Therapy across a Large Cell Therapy Network- through Technology and Decentralized Virtual Nurses: Preliminary Results

Blood (2023) 142 (Supplement 1): 254.

https://doi.org/10.1182/blood-2023-187253

Published: 2023

Journal Articles

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Jeremy S. Abramson, Aravind Ramakrishnan, Ana Alfonso Pierola, Ira Braunschweig, Guillaume Cartron, Catherine Thieblemont, Jose A. Pérez-Simón, Pere Barba, Peter A. Riedell, Carlos Solano, Thomas Gastinne, Alexandra LaCroce, Denise Thomas, Camille Poirot, Sarah Meadows, Kathryn J. Newhall, Daniel J. Lee, Mark G. Frattini, Emmanuel Bachy

Blood (2023) 142 (Supplement 1): 2110.

https://doi.org/10.1182/blood-2023-186570

Published: 2023

Journal Articles

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

Blood (2023) 141 (20): 2470–2482.

https://doi.org/10.1182/blood.2022018598

Published: 2023

Includes: Supplemental data

Journal Articles

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Blood (2021) 138 (22): 2278–2289.

https://doi.org/10.1182/blood.2021012021

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase II Single Arm Study of Nivolumab As Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma at Risk of Relapse or Progression

Carlos Bachier, Henning Schade, Behyar Zoghi, Aravind Ramakrishnan, Nirav N. Shah

Blood (2021) 138 (Supplement 1): 2455.

https://doi.org/10.1182/blood-2021-148139

Published: 2021

Journal Articles

Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)

Corey Cutler, MD MPH, FRCPC, Stephanie J. Lee, MDMPH, Sally Arai, MD MS, Marcello Rotta, MD, Behyar Zoghi, MD, Aravind Ramakrishnan, MD, David Eiznhamer, PhD, Olivier Schueller, PhD, Zhongming Yang, PhD, Laurie S. Green, MD, Sanjay K. Aggarwal, MD, Bruce R. Blazar, MD, Steven Z. Pavletic, MD MS, Madan Jagasia, MBBS, MS, MMHC

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-139445

Published: 2020

Journal Articles

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Minoo Battiwalla, MD, Carlos Bachier, MD, Vikas Bhushan, MD, Michael J. Eckrich, MD MPH, Alireza Eghtedar, MD, Haydar Frangoul, MD, Suman Kambhampati, MD, Shahbaz Malik, MD, Peter A. McSweeney, MD, Jeremy Pantin, MBBS, Aravind Ramakrishnan, MD, Hana Safah, MD, Paul J Shaughnessy, MD, Betsy Blunk, BSN, RN, BMTCN, Tonya Cox, BSN, RN, Rocky Billups, MS, Charles F. Lemaistre, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-139121

Published: 2020

Journal Articles

Monocyte and Fibroblast Directed Generation of a Marrow Vascular Niche

Surya S Kotha, Kiet T Phong, Amie Adams, Brian Hayes, PhD, Meredith A Roberts, Karol Bomsztyk, MD, Aravind Ramakrishnan, MD, Beverly Torok-Storb, PhD, Ying Zheng, PhD

Blood (2015) 126 (23): 3602.

https://doi.org/10.1182/blood.V126.23.3602.3602

Published: 2015

Journal Articles

U2AF1 Mutations Cause Allele-Specific Alterations in 3' Splice Site Recognition in Myeloid Malignancies

Janine O. Ilagan, PhD, Aravind Ramakrishnan, MD, Brian Hayes, PhD, Michele E. Murphy, Ahmad S. Zebari, Philip Bradley, PhD, Robert K. Bradley, PhD

Blood (2014) 124 (21): 1889.

https://doi.org/10.1182/blood.V124.21.1889.1889

Published: 2014

Journal Articles

SRSF2 Mutations Impair Hematopoietic Differentiation By Altering Exonic Splicing Enhancer Preference

Eunhee Kim, PhD, Janine O. Ilagan, PhD, Stanley Lee, PhD, Aravind Ramakrishnan, MD, Young Rock Chung, MS, Jean-Baptiste Micol, MD, Michele E. Murphy, Min-Kyung Kim, BS, Ahmad S. Zebari, Jacob Feala, Silvia Buonamici, PhD, Peter G Smith, PhD, H. Joachim Deeg, MD, Camille Lobry, PhD, Iannis Aifantis, PhD MSC, Robert K. Bradley, PhD, Omar Abdel-Wahab, MD

Blood (2014) 124 (21): 824.

https://doi.org/10.1182/blood.V124.21.824.824

Published: 2014

Journal Articles

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS

H. Joachim Deeg, Bart L. Scott, Min Fang, Howard M. Shulman, Boglarka Gyurkocza, David Myerson, John M. Pagel, Uwe Platzbecker, Aravind Ramakrishnan, Jerald P. Radich, Brenda M. Sandmaier, Mohamed Sorror, Derek L. Stirewalt, Wendy A. Wilson, Rainer Storb, Frederick R. Appelbaum, Ted Gooley

Blood (2012) 120 (7): 1398–1408.

https://doi.org/10.1182/blood-2012-04-423046

Published: 2012

Includes: Supplemental data

Journal Articles

Therapy of Myelodysplastic Syndrome (MDS) with Azacitidine Given in Combination with Etanercept: A Phase II Study.

Aaron L. Holsinger, Aravind Ramakrishnan, MD, Barry Storer, PhD, Pamela S. Becker, MD, PhD, Stephen Petersdorf, MD, H. Joachim Deeg, MD, Bart L. Scott, MD

Blood (2007) 110 (11): 1452.

https://doi.org/10.1182/blood.V110.11.1452.1452

Published: 2007

Journal Articles

Derivation, Characterization, and In Vitro Differentiation of Canine Embryonic Stem Cells.

Aravind Ramakrishnan, Brian Hayes, Sara R. Fagerlie, Szczepan Baran, Michael Harkey, Lynn Graf, Merav Bar, Ausra Bendoraite, Muneesh Tewari, Beverly Torok-Storb

Blood (2007) 110 (11): 4059.

https://doi.org/10.1182/blood.V110.11.4059.4059

Published: 2007

Journal Articles

Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity

Mineo Iwata, Manoj Pillai, Aravind Ramakrishnan, Robert C. Hackman, H. Joachim Deeg, Ghislain Opdenakker, Beverly Torok-Storb

Blood (2006) 109 (1): 85–92.

https://doi.org/10.1182/blood-2006-05-020289

Published: 2006

Includes: Supplemental data

Journal Articles

The stromal component of the marrow microenvironment is not derived from the malignant clone in MDS

Aravind Ramakrishnan, Norihiro Awaya, Eileen Bryant, Beverly Torok-Storb

Blood (2006) 108 (2): 772–773.

https://doi.org/10.1182/blood-2006-02-001479

Published: 2006

NARROW

Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Standardization of Outpatient Care after CAR-T Therapy across a Large Cell Therapy Network- through Technology and Decentralized Virtual Nurses: Preliminary Results

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

A Phase II Single Arm Study of Nivolumab As Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma at Risk of Relapse or Progression

Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Monocyte and Fibroblast Directed Generation of a Marrow Vascular Niche

U2AF1 Mutations Cause Allele-Specific Alterations in 3' Splice Site Recognition in Myeloid Malignancies

SRSF2 Mutations Impair Hematopoietic Differentiation By Altering Exonic Splicing Enhancer Preference

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS

Therapy of Myelodysplastic Syndrome (MDS) with Azacitidine Given in Combination with Etanercept: A Phase II Study.

Derivation, Characterization, and In Vitro Differentiation of Canine Embryonic Stem Cells.

Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity

The stromal component of the marrow microenvironment is not derived from the malignant clone in MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only